In India, Cipla and Dr Reddy’s Laboratories are also working on this off-patent opportunity, while Glenmark has already launched a generic for Liraglutide (another GLP-1 molecule). Sun Pharma, on the other hand, is chasing a novel molecule in this space which will enter phase 2 trials soon.
These facilities and investments bolster our capacity to support an increased demand for existing and future Lilly products across our diabetes and obesity portfolio,” the spokesperson said.
Our manufacturing organisation continues to execute well on the most ambitious expansion agenda in our company’s long history to help ensure people have access to the medicines they need,” Lilly said, highlighting that they are investing in scaling up production capacities.“Since 2020, we’ve invested more than $20 billion to build, expand and acquire facilities in the US, Europe and China.
The story "Eli Lilly to launch its obesity drug at competitive price in India in 2025" has 748 words across 27 sentences, which will take approximately 4 - 7 minutes for the average person to read.
Which news outlet covered this story?
The story "Eli Lilly to launch its obesity drug at competitive price in India in 2025" was covered 1 weeks ago by Business Standard, a news publisher based in India.
How trustworthy is 'Business Standard' news outlet?
Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news.
The outlet is headquartered in India and publishes an average of 111 news stories per day.
It's most recent story was published 3 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
